Cancer invasion and tissue remodeling - Cooperation of protease systems and cell types

APMIS

Volumn 107, Issue 1, 1999, Pages 120-127

  Danø, Keld ^a   Rømer, John ^b   Nielsen, Boye S ^a   Bjørn, Signe ^a   Pyke, Charles ^b   Rygaard, Jørgen ^c   Lund, Leif R ^a  

^a FINSEN LABORATORY   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c Mental Health Services CPH   (Denmark)

Author keywords

Cancer invasion; MMPs; Plasminogen; Proteases; Stromal cells; Tissue remodeling

Indexed keywords

PROTEINASE; UROKINASE;

BREAST CANCER; CANCER GROWTH; CANCER INVASION; COLON CANCER; ENZYME ACTIVITY; GENE TARGETING; GROWTH REGULATION; METASTASIS POTENTIAL; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0001071353     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1699-0463.1999.tb01534.x     Document Type: Review

References (102)

1. 1. Unkeless JC, Dano K, Kellerman GM, Reich E. Fibrinolysis associated with oncogenic transformation: Partial purification and characterization of the cell factor - a plasminogen activator. J Biol Chem 1974; 249:4295-305.
2. 2. Dano K, Reich E. Serine enzymes released by cultured neoplastic cells. J Exp Med 1978;147:745-57.
3. 3. Ossowski L, Biegel D, Reich E. Mammary plasminogen activator: Correlation with involution, hormonal modulation and comparison between normal and neoplastic tissue. Cell 1979;16:929-40.
4. 4. Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983; 35:611-9.
5. 5. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985;44:139-266.
6. 6. Pepper MS, Vassalli JD, Montesano R, Orci L. Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. J Cell Biol 1987;105: 2535-41.
7. 7. Grondahl-Hansen J, Lund LR, Ralfkiær E, Ottevanger V, Danø K. Urokinase-and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo. J Invest Dermatol 1988;90:790-5.
8. 8. Sappino, AP, Huarte J, Belin D, Vassalli JD. Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos. J Cell Biol 1989;109:2471-9.
9. 9. Teesalu, T, Blasi F, Talarico D. Expression and function of the urokinase type plasminogen activator during mouse hemochorial placental development. Dev Dynamics 1998;213:27-38.
10. 10. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-36.
11. 11. Talhouk RS, Bissell MJ, Werb Z. Coordinated expression of extracellular matrix-degrading proteinases and their inhibitors regulates mammary epithelial function during involution. J Cell Biol 1992;118:1271-82.
12. 12. Mignatti P, Rifkin, DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 1996;49:117-37.
13. 13. Lund LR, Romer J, Thomasset N, Solberg H, Pyke C, Bissell MJ, et al. Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development 1996;122: 181-93.
14. 14. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997;91:439-42.
15. 15. Rinkenberger JL, Cross JC, Werb Z. Molecular genetics of implantation in the mouse. Dev Genet 1997; 21:6-20.
16. 16. Blasi F, Vassalli JD, Dano K. Urokinase-type plasminogen activator: proenzyme, receptor and inhibitors. J Cell Biol 1987;104:801-4.
17. 2-terminal amino acid sequence and glycosylation variants. J Biol Chem 1990;265:6453-60.
18. 18. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, et al. Cloning and expression of the receptor for human urokinase-plasminogen activator, a central molecule in cell-surface plasmin-dependent proteolysis. EMBO J 1990;9:467-74.
19. 19. Dano K, Behrendt N, Brünner N, Ellis V, Ploug M, Pyke C. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fihrinolysis 1994;8:189-203.
20. 20. Ploug M, Østergaard S, Laurenhorg LB, Holm A, Danø K. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation. Biochemistry 1998;37:3612-22.
21. 21. Stephens RW, Pöllänen J, Tapiovaara H, Leung KC, Sim PS, Salonen EM, et al. Activation of pro-urokinase and plasminogen on human sarcoma cells: A proteolytic system with surface-bound reactants. J Cell Biol 1989;108:1987-95.
22. 22. Ellis V, Behrendt N, Dano K. Plasminogen activation by receptor-bound urokinase: a kinetic study with both cell-associated and isolated receptor. J Biol Chem 1991;266:12752-8.
23. 23. Ellis V, Danø K. Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation: A mechanistic model for receptor-mediated plasminogen activation. J Biol Chem 1993;268:4806-13.
24. 24. Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: Hormonally regulated serpins. Mol Cell Endocrinol 1990;88:1-19.
25. 25. Werb Z, Mainardi CL, Vater CA, Harris ED. Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N Engl J Med 1977;296:1017-23.
26. 26. Mignatti P, Robbins E, Rifkin DE. Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade. Cell 1986;47:487-98.
27. 27. Murphy G, Atkinson S, Ward R, Gavrilovic J, Reynolds JJ. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann NY Acad Sci 1992;667:1-12.
28. 28. Mazzieri B, Masiero L, Zanetta L, Monea S, Onisto M, Garbissa S, et al. Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell bound reactants. EMBO J 1997;15:2319-32.
29. 29. Rifkin DB, Mazzieri R, Munger JS, Noguera I, Sung J. Proteolytic control of growth factor availability. APMIS 1999;107:80-5.
30. 30. Bode W, Fernandez-Catalan C, Nagase H, Maskos K. Endoproteinase-protein inhibitor interactions. APMIS 1999; 107:3-10.
31. 31. Murphy G, Stanton H, Cowell S, Butler G, Knäuper V, Atkinson S, et al. Mechanisms for pro matrix metalloproteinase activation. APMIS 1999;107:38-44.
32. 32. Seiki M. Membrane-type matrix metalloproteinases. APMIS 1999;107:137-43.
33. 33. Fingleton BM, Heppner Goss KJ, Crawford HC, Matrisian LM. Matrilysin in early stage intestinal tumorigenesis. APMIS 1999;107:102-10.
34. 34. Balbin M, Pendás AM, Uria JA, Jiménez MG, Freije, JP, Löpez-Otin C. Expression and regulation of collagenase-3 (MMP-13) in human malignant tumors. APMIS 1999;107:45-53.
35. 35. Werb Z, Vu TH, Rinkenberger JL, Coussens LM. Matrix-degrading proteases and angiogenesis during development and tumor formation. APMIS 1999;107: 11-8.
36. 36. Lochter A, Bissel MJ. An odyssey from breast to bone: Multi-step control of mammary metastases and osteolysis by matrix metalloproteinases. APMIS 1999;107: 128-36.
37. 37. Henriet P, Blavier L, DeClerck YA. Tissue inhibitors of metalloproteinases (TIMP) and proliferation. APMIS 1999;107:111-9.
38. 38. Skriver L, Larsson LI, Kielberg V, Nielsen LS, Andresen PB, Kristensen P, et al. Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J Cell Biol 1984;99:753-8.
39. 39. Kristensen P, Pyke C, Lund LR, Andreasen PA, Danø K. Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma. Histochem. 1990;93:559-66.
40. 40. Grøndahl-Hansen J, Ralfkiær E, Kirkeby LT, Kristensen P, Lund LR, Danø K. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol 1991;138:111-7.
41. 41. Pyke C, Kristensen P, Ralfkiaer E, Grøndahl-Hansen J, Eriksen J, Blasi F, et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991;138:1059-67.
42. 42. Pyke C, Ralfkiør E, Rønne E, Høyer-Hansen G, Kirkeby L, Dane K. Immunohislochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathol 1994;24:131-8.
43. 43. Pyke C, Salo S, Ralfkiør E, Rømer J, Danø K, Tryggvason K. Laminin-5 is a marker of invading cancer cells in some human carcinomas and is co-expressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res 1995;55:4132-9.
44. 44. Pyke C, Kristensen P, Ralfkiær E, Eriksen J, Danø K. The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res 1991;51:4067-71.
45. 45. Pedersen H, Grøndahl-Hansen J, Francis D, Østerlind K, Hansen HH, Danø K, et al. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 1994;54:120-3.
46. 46. Nielsen HJ, Pappot H, Christensen IJ, Brünner N, Thorlacius-Ussing O, Moesgaard F, et al. Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. Br Med J 1998;316:829-30.
47. 47. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993;53: 2513-21.
48. 48. Look MP, Foeckens JA. Clinical relevance of the urokinase plasminogen activator system in breast cancer. APMIS 1999;107:150-9.
49. 49. Bajou K, Noel A, Gerard RD, Brünner N, Holst-Hansen C, Skobe M, et al. Absence of host plasminogen activator inhibitor-1 prevents cancer invasion and vascularization. Nat Med 1998;4:923-8.
50. 50. Pyke C, Ralfkiaer E, Tryggvason K, Danø K. Messenger RNA for two type IV collagenases is located in stromai cells in human colon cancer. Am J Pathol 1993;142:359-65.
51. 51. Gray ST, Yun K, Motoori T, Kuys YM. Interstital collagenase gene expression in colonic neoplasia. Am J Pathol 1993;143:663-71.
52. 52. Ohtani Y, Okazaki I, Arai M, Kameyama K, Wada N, Maruyama K, et al. Gene expression of interstitial collagenase (matrix metalloproteinase 1) in gastrointestinal tract cancers. J Gastroenterol 1994;29:391-7.
53. 53. McDonnel S, Navre M, Coffey RJ Jr, Matrisian LM. Expression and localisation of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcin 1991;4:527-33.
54. 54. Wolf C, Rouyer N, Lutz Y, Adida C, Loriot M, Belocq JP, et al. Stromelysin-3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci USA 1993;90:1843-7.
55. 55. Okada A, Bellocq JP, Rouyer N, Chenard MP, Rio MC, Chambon P, Basset R Membrane-type matrix metalloproteinase gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 1995;92:2730-4.
56. 56. Lund LR, Rømer J, Renne E, ElHs V, Blasi F, Danø K. Urokinase receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor-β1 in human A549 lung carcinoma cells. EMBO J 1991;10:3399-407.
57. 57. Uría JA, Jiménez MG, Balbin M, Freije JP, Lopez-Otin C. Differential effects of TGF-β on the expression of collagenase-1 and collagenase-3 in human fibroblasts. J Biol Chem 1997;273:9769-77.
58. 58. Pyke C, Græm N, Ralfkiær E, Rønne E, Høyer-Hansen G, Brunner N, Danø K. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 1993;53:1911-5.
59. 59. Basset P, Wolf C, Chambon P. Expression of the stromelysin-3 gene in fibroblastic cells of invasive carcinomas of the breast and other human tissues. Breast Cancer Res Treat 1993;24:185-93.
60. 60. Poulsom R, Hanby AM, Pignatelli M, Jeffery RE, Longcroft JM, Rogers L, et al. Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cells carcinomas of the skin. J Clin Pathol 1993;46:429-36.
61. 61. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, et al. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 1993;67:1126-31.
62. 62. Polette M, Clavel C, Cockett M, Girod de Bentzmann S, Murphy G, Birembaut P, Detection and localisation of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. Inv Metast 1993;13:31-7.
63. 63. Blanchi E, Cohen RL, Thor AT, Todd RF, Mizukami IF, Lawrence DA, et al. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 1994;54:861-6.
64. 64. Nielsen BS, Sehested M, Timshel S, Pyke C, Danø K. Messenger RNA for urokinase plasminogen activator (uPA) is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest 1996;74:168-77.
65. 65. Nielsen BS, Sehested M, Kjeldsen L, Borregaard N, Rygaard J, Dano, K. Expression of the matrix metalloprotease-9 in vascular pericytes in human breast cancer. Lab Invest 1997;77:345 55.
66. 66. Petersen OW, Rannov-Jessen L, Weaver VM, Bissel MJ. Differentiation and cancer in the mammary gland: Shedding light on an old dichotomy. Adv Cancer Res 1998;75:135-61.
67. 67. Sappino AP, Belin D, Huarte J, Hirschel-Scholtz S, Saurat JH, et al. Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest 1991;88:1073-9.
68. 68. Airola K, Johansson N, Kariniemi AL, Kahari VM, Saarialho-Kere UK. Human collagenase-3 is expressed in malignent squamous epithelium of the skin. J Invest Dermatol 1997;109:225-31.
69. r 72,000 and 92,000 type TV collagenases in human skin cancers by in situ hybridization. Cancer Res 1992;52:1336-41.
70. 70. Danø K, Grondahl-Hansen J, Eriksen J, Nielsen BS, Rømer J, Pyke C. The receptor for urokinase plasminogen activator. Stromal cell involvement in extracellular proteolysis during cancer invasion. In: Barrett AJ, Bond J, editors. Proteolysis and Protein Turnover. London: Portland Press; 1993: 239-45.
71. 71. MacDougall JR, Matrisian LM. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Met Rev 1995;14L:351-62.
72. 72. Hewitt R, Danø K. Stromal cell expression of components of matrix degrading systems in human cancer. Enzyme and Protein 1996;49:163-73.
73. 73. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996;149:273-82.
74. 74. Uría JA, Ståhle-Bäckdahl M, Seiki M, Fueyo A, Lóp-ez-Otin C. Regulation of collagenase-3 expression in breast carcinomas is mediated by stromal-epithelial cell interactions. Cancer Res 1997;57:4882-8.
75. 75. Johnsen M, Lund LR, Romer J, Almholt K, Danø K. Cancer invasion and tissue remodeling: Common themes in proteolytic matrix degradation. Curr Opin Cell Biol 1998;10:667-71.
76. 76. Larsson LI, Skriver L, Nielsen LS, Grondahl-Hansen J, Kristensen P, Danø K. Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse. J Cell Biol 1984;98:894-903.
77. 77. Kristensen P, Eriksen J, Blasi F, Danø K. Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. J Cell Biol 1991;115:1763-71.
78. 78. Lefebvre O, Wolf C, Limacher JM, Hutin P, Wendling C, LeMeur M, et al. The breast cancer-associated stromelysin-3 gene is expressed during mouse mammary gland apoptosis. J Cell Biol 1992;119:997-1002.
79. 79. Romer J, Lund LR, Eriksen J, Ralfkiær E, Zeheb R, Gelehrter TD, et al. Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds. J Invest Dermatol 1991;97:803-11.
80. 80. Rømer J, Lund LR, Eriksen J, Pyke C, Kristensen P, Danø K. The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during reepithelialization of mouse skin wounds. J Invest Dermatol 1994;102:519-22.
81. 81. Romer J, Bugge TH, Pyke C, Lund LR, Flick MJ, Degen JL, Dane K. Impaired wound healing in plasminogen-deficient mice. Nature Medicine 1996;2:287-92.
82. 82. Vaalamo M, Weckroth M, Puolakkainen P, Kere J, Saarinen P, Lauharanta J, et al. Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds. Br J Dermatol 1996;135:52-9.
83. 83. Basset P, Wolf C, Chambon P. Expression of the Stromlysin-3 gene in fibroblastic cells of invasive carcinomas of the breast and other human tissues: A review. Breast Cancer Res Treat 1993;24:185-93.
84. 84. Pedersen H, Brunner N, Francis D, Østerlind K, Rønne E, Hansen HH, Danø K, Grandahl-Hansen J. Prognostic impact of urokinase, urokinase receptor and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994;54:4671-5.
85. 85. Stephens RW, Brünner N, Jänicke F, Schmitt M. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 1999 (in press).
86. 86. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Danø K, Brünner N. Plasma urokinase receptor in colorectal cancer patients: relation to prognosis. J Natl Cancer Inst, submitted.
87. 87. Brünner N, Nielsen HJ, Hamers M, Christensen IJ, Thorlacitis-Ussing O, Stephens RW. The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer. APMIS 1999; 107:160-7.
88. 88. Duffy MJ, O'Grady P, Devaney D, O'Sorian L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator, a marker for agressive breast carcinomas. Cancer 1988;62:531-3.
89. 89. Groøndahl-Hansen J, Peters HA, van Putten WLJ, Look MP, Pappot H, Ronne E, et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995;1:1079-87.
90. 90. Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen-deficency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995;9:794-807.
91. 91. Plopcis VA, Carmeliet P, Vazirzadeh S, Van VI, Moons L, Plow EF, et al. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 1995;92:2585-93.
92. 92. Bugge TH, Kombrinck KW, Flick MJ, Daugherty CC, Danton MJS, Degen JL. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 1996;87:709-19.
93. 93. Bugge TH, Lund L, Kombrinck KK, Nielsen BS, Holmback K, Drew AF, et al. Reduced metastasis of polyoma middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 1998;16: 3097-104.
94. 94. Schuster V, Mingers AM, Seidenspinner S, Nussgens Z, Pukrop T, Kreth HW Homozygous mutations in the plasminogen gene of two unrelated girls with Ligneous conjunctivitis. Blood 1997;90:958-66.
95. 95. Schott D, Dempfle CE, Beck P, Lierman A, Mohr-Pennert A, Goldner M, Mehlem P, Azuma H, Schuster V, Mingers A, Schwarz HP, Kramer MD. Successful replacement therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency. New Engl J Med (in press).
96. 96. Mingers AM, Philapitsch A, Zeitler P, Schuster V, Schwartz HP, Kreth HW. Human homozygous type 1 plasminogen deficiency and Ligneous conjunctivitis. APMIS 1999;107:62-72.
97. 97. Bouisson M. Ophthalmie sur-aigue avec formation de pseudomembranes à la surface de la conjonctive. Ann Oculist 1847;17:100-4.
98. 98. Bateman JB, Pettit TH, Isenberg SJ, Simons KB. Ligneous conjunctivitis: an autosomal-recessive disorder. J Pediatr Ophthalmol Strabismus 1986;23:137-10.
99. 99. Hydayat AA, Riddle PJ. Ligneous conjunctivitis. A clinicopathologic study of 17 cases. Ophthalmology 1987;94:949-59.
100. 100. Drew AF, Kaufman AH, Kombrinck KW, Danton MJ, Daugherty CC, Degen JL, et al. Ligneous conjunctivitis in plasminogen-deficient mice. Blood 1998;91:1616-24.
101. 101. Mingers AM, Heimburger N, Zeller P, Kreth HW, Schuster V. Homozygous type 1 plasminogen deficiency. Semin Thromb Hemost 1997;23:259-64.
102. 102. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998;58:1048-51.